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Ovarian Cancer (OC) is the first death cause by gynaecological cancer in developed 
countries and the third cause of gynaecological cancer in the world.  
Detecting irresectable disease is crucial to select surgical candidates and Peritoneal 
Carcinomatosis (PC) depiction helps to get a complete debulking without residual 
disease >1cm, the best prognostic predictor in advanced OC. 
CT is the elective technique for abdominal imaging, although its accuracy for PC in OC 
and cytoreduction success prediction ability is limited. PET/CT is considered for 
systemic evaluation in OC however, it is not a reference standard for PC. 
PC presents as high signal foci in DWI, with higher contrast than conventional MRI. 
Whole Body DWI with Background Suppression MRI (WB-DWIBS/MRI) combines 
conventional anatomic with Diffusion Weighted Imaging (DWI). 
This study aims to assess the diagnostic performance and tumour burden correlation of 
WB-DWIBS/MRI in ovarian PC using PCI, referred to cytoreduction surgery as 
standard reference. 
MATERIAL AND METHODS: 
Our local ethical board approved this prospective study and all participants signed 
written informed consent. 50 out of 217 consecutive patients with disseminated primary 
or recurrent OC were eligible for cytoreduction and WB-DWIBS/MRI.  
Peritoneal Cancer Index (PCI) scores (0-3) tumour burden in 13 anatomical regions, 
hence global ranging 0-39. Two radiologists (R1 and R2) preoperatively assessed PCI 
and the gynaecologic-oncologist team after.  
Diagnostic performance was calculated for each of the PCI regions and globally. We 
evaluated interobserver agreement using Cohen´s Kappa, statistic differences with the 
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McNemar test (significativity p<0.05) and tumour burden with Pearson correlation test 
for R1 and R2. 
RESULTS: 
Histology was epithelial OC in 72% (36/50) and complete cytoreduction was achieved 
in 39/50 patients. Correlation test was 0.762 (p<0.001) for R1 and R2 0.642 (p<0.001). 
Global diagnostic performance was Sensitivity 0.84; Specificity 0.89; positive 
predictive value 0.72; negative predictive value 0.92; Accuracy 0.89; Kappa 0.41. 
DISCUSION: 
Global tumour burden was low (average PCI 7). Pelvis and right hypochondrium 
showed the highest positive rate and diagnostic performance. The intestinal regions 
presented the lowest positive rate. 
Although only a few used PCI, previous studies reported similar results than ours with 
higher Sensitivity when compared to CT and PET/CT. 
CONCLUSION: 
WB-DWIBS/MRI is a reliable imaging technique to preoperatively quantify and depict 
PC of ovarian origin in order to get a complete cytoreductive surgery. 
 
KEYWORDS: 
Peritoneal carcinomatosis  
MR imaging 
Ovarian cancer  
Whole-body magnetic resonance imaging (WB-MRI) 
Diffusion weighted imaging (DWI) 






































































OC Ovarian Cancer 
PC Peritoneal Carcinomatosis 
PCI Peritoneal Cancer Index 
CT Computed Tomography 
PET/CT Positron Emission Tomography CT with 18-fluorodeoxyglucose 
HIPEC Hyperthermic Intraperitoneal Chemoperfusion 
DWI Diffusion Weighted Imaging 
WB-DWIBS/MRI Whole Body DWI with Background Suppression MRI 
 
INTRODUCTION 
Ovarian Cancer (OC) is the first death cause by gynaecological cancer in developed 
countries and it is globally the third cause of gynaecological cancer, with an incidence 
of 3412 and a 5-year prevalence for general population 7939 for 2017 in Spain, similar 
to other industrialized countries [1, 2]. The most common OC histology is epithelial, 
and up to 65% are diagnosed at stages III and IV with Peritoneal Carcinomatosis (PC) 
and nodal dissemination, with high mortality associated [2, 3]. 
Treatment of choice in epithelial OC is primary surgical cytoreduction followed by 
platinum-based adjuvant chemotherapy [4]. Achieving a complete surgical debulking, 
without residual disease >1cm (R0), is the best prognostic predictor in advanced OC [5]. 
Occasionally, if primary surgery cannot be initially performed [5], an interval surgery 
after 3 cycles of neoadjuvant chemotherapy might be considered. Secondary 




































































Preoperative detection of irresectable disease is crucial to select surgical candidates, the 
detection and location of peritoneal seeding in OC is useful for planning an accurate 
surgery.  
Laparoscopy has been proposed as a preoperative evaluation using the Fagotti score [6]. 
This system assesses 8 peritoneal structures and assigns a score 0-2. If global scoring is 
8, then the predictive positive value (PPV) of a suboptimal surgical result is 100%. 
However, laparoscopy is an invasive technique, and it cannot evaluate the 
retroperitoneum nor the tumour posterior to the gastrosplenic ligament and in the lesser 
sac [7]. 
Peritoneal Cancer Index (PCI) [8] was described for PC quantification in surgical 
cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC). 
PCI is a region-wise scoring system that assesses 13 anatomic regions with a range 0-3 
each, attending the largest lesion in each region (No tumour LS0; up to 0.5 cm LS 1; up 
to 5 cm LS 2 and more than5 cm or confluent LS 3) (Fig.2) thereby was calculated as 
the addition of all regional scoring in each patient, with a total burden range from 0 to 
39. 
PCI is used in digestive carcinomatosis candidates for cytoreduction and HIPEC, and 
not so often in ovarian carcinomatosis given that the only accepted prognostic factor is a 
complete debulking without residual disease >1cm, whereas HIPEC is still under 
discussion in advanced OC [9]. 
Currently, no imaging tool is capable of predicting the success of a complete resection. 
Different imaging techniques are used in preoperative PC assessment describing several 




































































Due to its availability and reproducibility, Computed Tomography (CT) is the central 
imaging technique for abdominal imaging and when using a dedicated protocol, CT 
correlates well with surgical PCI [12]. 
CT is recommended for staging and restaging for gynaecologic malignancies by 
American College of Radiology (ACR) and National Comprehensive Cancer Network 
(NCCN) guidelines. CT accuracy for PC in OC and capability for predicting success of 
cytoreductive surgery is limited, although when evaluated with CA-125 it may predict 
prognosis [13, 14]. 
Positron Emission Tomography CT with 18-fluorodeoxyglucose (PET/CT) can be 
considered for systemic evaluation in gynaecologic malignancies, especially in OC 
although it is not yet stablished as a reference standard when compared to CT for PC 
depiction [15]. 
Conventional MRI is useful in peritoneal carcinomatosis [16], however it is inferior to 
PET/CT [17, 18] and similar to CT [19].  
Diffusion Weighted Imaging (DWI) is obtained by using high-energy short-time MR 
radiofrequency pulses, b value expresses the strength of potentiation in diffusion. Using 
high b values (b 
water movement restriction that can be pathologic (tumour, blood and others) or not 
lmost no signal of the rest of the anatomy.  
Dynamic contrast-enhanced imaging and DWI improve the capability of tumour pelvic 
recurrence characterization [20] and adding high b DWI to routine MRI, raises the 
diagnostic performance for peritoneal metastases [21-24]. 
When DWI is combined with conventional imaging of the entire body for anatomic 
reference and characterization of findings, we obtain Whole Body DWI with 




































































This study aims to assess the diagnostic performance and tumour burden correlation of 
WB-DWIBS/MRI in ovarian PC using PCI, referred to cytoreduction surgery as 
standard reference. 
 
MATERIAL AND METHODS 
Study design 
This is an observational prospective single-institutional non-comparative diagnostic 
performance study of WBMRI/DWIBS versus pathologic proven surgical standard of 
reference. Institutional review board approval was obtained, and all patients signed 
written informed consent. 
 
Study population 
Inclusion criteria were: Suspected diagnosis of primary or recurrent ovarian carcinoma 
by CA-125 raise and imaging findings. Exclusion criteria were: Claustrophobia, known 
renal impairment (Creatinine > 1.5 mg/dl or glomerular filtration rate <60 
ml/min/1.73m2), contraindications to hyoscine butyl-bromide (allergies, glaucoma, 
history of bowel obstruction or urinary retention), non-operable patients and non-
resectable disease [7]. Patients considered for interval debulking surgery were not 
considered for the study. 
From June 2014 to January 2017, 217 consecutive patients presented in our institution 
and were evaluated in interdisciplinary meeting, 108 were considered for initial 
chemotherapy and 109 were candidates for cytoreduction and they were offered to 
undergo a WBMRI/DWIBS exam. 61 patients met all the inclusion criteria (Fig. 1), 11 








































































Patients drank 1 litre of pure pineapple juice 2 hr before as a negative oral contrast 
agent. We injected 20 mg diluted in 100 cc saline solution hyoscine butyl-bromide, 50 
cc at the beginning of the examination and the other 50 cc before the DWIBS sequence. 
Intravenous contrast gadobutrol 1 mmol/ml (0, 2 ml/kg weight) was given at an 
injection rate 2ml/s (MEDRAD® Spectris Solaris EP Injection System). 
Imaging was performed on a 1.5 T system (Ingenia, Philips Healthcare, Best, The 
Netherlands) (Table 1) with head/neck and two body phased-array coils for anatomic 
covering from head to mid thighs [26] [25].  
Coronal and axial single-shot T2 weighted turbo spin echo (T2TSE) and volumetric 
3DT1-weighted fat sat gradient-echo (3DT1GE) for anatomic evaluation and DWIBS 
imaging (b-values: 0 and 1000 s/mm2) were obtained in the coronal plane.  
In a dedicated MR workstation (IntelliSpace Portal. Version 606.20039, Philips Medical 
Systems Nederland B.V.), we obtained reformatted Maximum Intensity Projection 
(MIP) images in the axial and sagittal planes and colour derived maps using T2TSE and 
3DT1GE as a reference layer and DWIBS MIP-DWIBS as a colour functional overlay 
(alpha blending 50%). 
 
Imaging analysis 
Two radiologists (R1 and R2 with 10 and 5 years in abdominal imaging respectively) 





































































Tumour detection was assessed with DWIBS and the findings were correlated with 
T2TSE and 3DT1GE sequences for anatomic location.  
Any size nodular, plaque or linear intrabdominal high signal foci on DW were 
considered positive and documented for every region (13) in each patient, based on PCI. 
If a nodule was detected in conventional images but showed no signal in DWI, it was 
considered positive. Peritoneal surface contrast enhancement, ascites or adhesions were 
not considered as peritoneal tumour. We did not evaluate Apparent Diffusion 
Coefficient (ADC) given the small size of some implants. 
Both radiologists used the PCI (Fig. 2) [8] for assessing regional diagnostic 
performance in 50 cases.  
 
Standard of reference 
OC treatment naïve patients with indication for surgical resection were considered to 
undergo primary cytoreduction, and those who had prior surgery were considered to 
undergo non-primary cytoreduction. 
All the patients were operated by the same gynaecologic surgeon and general surgeon. 
The same two pathologists evaluated all samples. All the pathologists and surgeons had 
more than 15 years each in gynaecologic oncology. 
Regions were assessed during surgery according to the PCI system and specimens were 
labelled for subsequent pathological confirmation. 
 
Statistical analysis: 
SPSS v21.0 software (IBM) was used with p-values <0.05 indicating statistical 
significance. WBMRI/DWIBS findings were compared with surgery obtaining 




































































accuracy. Statistic differences between both techniques were calculate with the two-
tailed McNemar test and in order to avoid biases Bonferroni correction was used. 
<0.4, Fair; <0.6, Moderate; <0.8, Substantial; >0.8 Perfect). Surgical and preoperative 
global PCI was assessed with correlation Pearson test. 
 
RESULTS 
A total of 50 patients were selected for the study and peritoneal seeding was 
pathologically confirmed after surgery in 13 PCI regions (Fig 2) 
Table 2 shows the clinical outcome. Surgery was delayed in some patients due to acute 
comorbidities (acute infections, renal impairment and others). 
Almost all the patients (94%, 47/50) presented primary gynaecologic disease, 88% 
(44/50) were primary gynaecologic malignancies and 76% (38/50) were of ovarian 
origin and histology was epithelial in 72% (36/50). 
Figure 3 presents the frequency of disease detected in each region and Table 3 
diagnostic performance of WBMRI/DWIBS for R1 and R2.  
The global average surgical PCI was 7.42 ± 5.675, 7.08 ± 5.865 for R1 and for R2, 7.06 
± 5.245. Pearson correlation test was 0.762 (p<0.001) for R1 and R2 0.642 (p<0.001) 
(Figure 4). 
Overall positive scoring (Score values 1-3) for surgical findings, R1, and R2 were 
28.46%, 30.77 and 24.15% respectively (Fig. 5) 
Global diagnostic performance was calculated as the average of regional performances 
presented statistical significance (p<0.05) for both observers when compared with 




































































Interobserver agreement is globally fair to moderate although it is moderate to 
substantial in 6 out of 13 regions evaluated. 
Regional evaluation showed that pelvis presented the highest number of positives for 
both observers and surgery, with a high sensitivity although a moderate specificity. 
Central region is the second with highest rate of positives with a moderate sensitivity 
and high specificity for both observers. 
Central region and bowel loops show a low detection rate, although they present a good 
diagnostic performance. 
Accuracy is over 0.86 in all the regions for R1 and above 0.8 in 6/13 regions for R2 and 
global accuracy is 0.89 and 0.8 respectively. 
 
DISCUSSION: 
This prospective study evaluated the diagnostic performance and tumour burden 
quantification using WB-DWIBS/MRI in ovarian PC, using imaging PCI referred to 
surgical PCI in patients undergoing primary or secondary cytoreduction. Those patients 
receiving interval debulking surgery after 3 cycles of chemotherapy were excluded of 
the study, given that tumour necrosis and bleeding might be a false positive source [27]. 
Secondary cytoreduction is a different clinical situation, they are patients that recurred 
sometime after primary surgery therefore, it can be considered new disease.  
We adopted PCI [8] as a reproducible mean for PC distribution and tumour burden 
quantification for different imaging techniques [12, 14, 16, 28-33] and surgical findings; 
others evaluated WB-MRI/DWIBS regional ovarian carcinomatosis [24, 26, 34-37] 
attending non-PCI anatomical compartments, so local assessment is difficult to compare 




































































Global tumour burden was low (average PCI 7) and most of the regions showed no 
peritoneal implants because many of the patients with high tumour burden did not fulfil 
operability or resectability criteria, therefore they were not eligible for this study. 
We found a significative correlation in peritoneal tumour burden of MRI compared with 
surgery, that is better than reported for PET/CT or CT [15]. 
Pelvis followed by right hypochondrium, showed the highest positive rate and 
diagnostic performance. The first because it is the site of the primary tumour and 
peritoneal implants deposit by gravity effect, and the second because of the high 
contrast of the tumour with the liver surface (Fig. 6), whose signal is almost null in 
DWIBS, compared to the lack of density differences in CT or PET/CT. 
The intestinal regions presented the lowest positive rate because massive affection may 
preclude surgical resection if it obliges to multiple anastomosis. The central zone 
showed a variable positive rate, partly because mesentery root infiltration may also 
contraindicate surgery and because omental infiltration is difficult to assign in one of 
these compartments. Moreover, assignation of a lesion to one or another compartment 
was sometimes challenging. 
WB-DWIBS/MRI global and regional accuracies are statistically significative, with 
good values although there are regional variations. 
Our results are in line with previous studies. To the best of our knowledge, only one 
study evaluated ovarian carcinomatosis with WB-DWIBS/MRI using PCI [31] with 
higher Sensitivity when compared to CT and PET/CT, however in a fifteen-patient 
sample. 
Other studies assessing gynaecological cancer with DWIBS provided similar results, 
with better diagnostic performance than CT, although with variable designs, sample 




































































Our diagnostic performance in region 5 overlaps with the recently described for splenic 
infiltration [38] both for CT and MRI. The findings can be partially explained by the 
physiologic high DWI signal of the spleen, that may difficult tumour detection. 
However, splenic infiltration does not preclude cytoreduction and miliary 
carcinomatosis and different key peritoneal regions must be evaluated. 
When compared to PET/CT, WB-DWIBS/MRI shows better [26, 37] or at least similar 
[23, 31] diagnostic performance for PC. Some studies provided better results for 
PET/CT, though MR did not combine DWI sequences [17] neither they were considered 
in some initial meta-analysis [18]. However, more recent ones reported better 
performance than PET/CT when using WB-DWIBS/MRI [39]. 
Our regional sensitivites are very close to the reported [21, 30-31] when evaluating WB-
DWIBS/MRI with PCI for local diagnostic performance, although with higher 
specificities in almost every region, probably because the use of higher b values 
(b1000), except pelvis that also showed better sensitivity.  
One limitation is that this is a single institutional study. There can be an occult selection 
bias since the patients selected for the study were also candidates for cytoreduction, so 
that resectability itself and areas that may contraindicate resectability might be 
underevaluated. 
Although patients undergoing interval-debulking surgery were excluded, more than half 
of the sample are postoperated patients, therefore diagnostic performance may have 
been affected. T2-Shine-through may be a source of false positive findings in DWIBS 
sequence, especially in dense fluids such as blood, mucin or coagulative necrosis that 
keep hyperintense signal in high b DWIBS imaging [27] but they can be confirmed with 
other sequences (T2 or T1*-contrast enhanced). Another major limitation is that we did 




































































PET/CT, given that patients were referred by different institutions, with various initial 
modalities and wide variations in imaging protocols. 
However, this is a prospective nature study of a moderately large very homogeneous 
sample where almost all patients were OC, and we present a quantitative approach of 
imaging findings related to surgery. 
Even though it is out of the scope of this study, WB-DWIBS/MRI can evaluate nodal 
and supradiaphragmatic dissemination. 
Given that ADC was not evaluated, further research may be needed to stablish a cutoff 
point for DW signal intensity similarly to standard uptake value (SUV) in PET/CT. 
As a conclusion, WB-DWIBS/MRI is a reliable imaging technique helpful to 
preoperatively quantify and depict peritoneal carcinomatosis in ovarian cancer in order 





































































TABLES AND FIGURES: 
Table 1: Sequence protocol of WB-DWIBS/MRI. DWIBS, Diffusion Weighted 
Imaging with Background Suppression; 3DT1GE, 3D volumetric Gradient Echo T1; 
THRIVE T1-weighted High Resolution Isotropic Volume Examination; SPAIR 
Spectrally Adiabatic Inversion Recovery; mDIXON multi-echo 2-point DIXON. 
Table 2: Clinical characteristics and outcome in the patients included. 
Table 3: Global and regional diagnostic performance of WB-DWIBS/MRI for both 
observers (R1 and R2) and surgery. 
Figure 1: Flowchart showing the sample selection criteria for the study. 
Figure 2: PCI diagram. 
Figure 3: Percentage of positives detected in the different peritoneal regions using PCI 
system, with WB-DWIBS/MRI for observers R1 (a, d) and R2 (b, e) compared with 
surgery (c, f). 
Figure 4: Correlation between surgical total PCI (vertical axis) and WB-DWIBS/MRI 
total PCI (horizontal axis) for R1 (a) and R2 (b). 
Figure 5: Bar chart shows overall PCI score distribution considering 650 (13 × 50) 
observations. 
Figure 6: Coronal native images weighted in T2TSE (a), 3DGET1 (b) and DWIBS (c) 
and red-scale DWIBS fused imaging with T2 (d) 3DGET1 (e) in the same planes as 
above and in para-aortic plane (f). 
Asterisks show ascites in both flanks and pelvis. Peritoneal carcinomatosis (white 
arrowheads) is shown in flanks, greater omentum, subdiaphragmatic and perihepatic 
spaces, left hypochondrium and pelvis surrounding ascites. Para-aortic and pericaval 
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Age *(years) mean, (sd) 56.00 (12.69)
Time to surgery (days) median, (range) 12 (37)
CA-125 prior surgery (U/ml) Median,(range) 167.5 (11760.8)
Primary site Total (n=50) 
Ovary 38 
Fallopian tube 1 
Uterus 2 
Cervix 3 
Other non-malignant Gynecologic 3 
Other malignant non-Gynecologic 3 











Histology Total (n=50) 
Serous adenocarcinoma 28 
Clear cell 4 
Mixed Müllerian Malignant Tumor (MMMT) 3 
Serous cystadenoma 2 
Endometriosis 2 
Borderline Tumor  2 
Endocervical Adenocarcinoma  1 
Breast Adenocarcinoma 1 
Biliary adenocarcinoma 1 
Endometrioid Adenocarcinoma 2 
Adenosarcoma 1 
Leiomyoma 1 
Gastro Intestinal Stromal Tumor (GIST) 1 
Borderline Mucinous Tumor  1 
Surgical outcome Total (n=50) 
Microscopic (Complete) 39 
Macroscopic <1 cm (Optimal) 7 
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